Literature DB >> 26089723

Have we given up on a cure for ovarian cancer?

S A Narod1.   

Abstract

Entities:  

Year:  2015        PMID： 26089723      PMCID： PMC4462534          DOI： 10.3747/co.22.2517

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  9 in total

1.  The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.

Authors:  Barry Rosen; Stephane Laframboise; Sarah Ferguson; Jason Dodge; Marcus Bernardini; Joan Murphy; Yakir Segev; Ping Sun; Steven A Narod
Journal:  Gynecol Oncol       Date:  2014-07-12       Impact factor: 5.482

2.  Progression-free survival: helpful biomarker or clinically meaningless end point?

Authors:  Alan P Venook; Josep Tabernero
Journal:  J Clin Oncol       Date:  2014-11-03       Impact factor: 44.544

3.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Authors:  Robert A Burger; Mark F Brady; Michael A Bookman; Gini F Fleming; Bradley J Monk; Helen Huang; Robert S Mannel; Howard D Homesley; Jeffrey Fowler; Benjamin E Greer; Matthew Boente; Michael J Birrer; Sharon X Liang
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

5.  Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Authors:  Amit M Oza; David Cibula; Ana Oaknin Benzaquen; Christopher Poole; Ron H J Mathijssen; Gabe S Sonke; Nicoletta Colombo; Jiří Špaček; Peter Vuylsteke; Holger Hirte; Sven Mahner; Marie Plante; Barbara Schmalfeldt; Helen Mackay; Jacqui Rowbottom; Elizabeth S Lowe; Brian Dougherty; J Carl Barrett; Michael Friedlander
Journal:  Lancet Oncol       Date:  2014-12-04       Impact factor: 41.316

6.  Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.

Authors:  John R McLaughlin; Barry Rosen; Joel Moody; Tuya Pal; Isabel Fan; Patricia A Shaw; Harvey A Risch; Thomas A Sellers; Ping Sun; Steven A Narod
Journal:  J Natl Cancer Inst       Date:  2012-12-20       Impact factor: 13.506

7.  Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.

Authors:  Angeles Alvarez Secord; Jason Cory Barnett; Jonathan A Ledermann; Bercedis L Peterson; Evan R Myers; Laura J Havrilesky
Journal:  Int J Gynecol Cancer       Date:  2013-06       Impact factor: 3.437

8.  Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.

Authors:  Tomasz Byrski; Rebecca Dent; Pawel Blecharz; Malgorzata Foszczynska-Kloda; Jacek Gronwald; Tomasz Huzarski; Cezary Cybulski; Elzbieta Marczyk; Robert Chrzan; Andrea Eisen; Jan Lubinski; Steven A Narod
Journal:  Breast Cancer Res       Date:  2012-07-20       Impact factor: 6.466

9.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis
Journal:  Lancet Oncol       Date:  2014-05-31       Impact factor: 41.316
  9 in total
  2 in total

1.  Comparative Study of Multicellular Tumor Spheroid Formation Methods and Implications for Drug Screening.

Authors:  Maria F Gencoglu; Lauren E Barney; Christopher L Hall; Elizabeth A Brooks; Alyssa D Schwartz; Daniel C Corbett; Kelly R Stevens; Shelly R Peyton
Journal:  ACS Biomater Sci Eng       Date:  2017-03-13

Review 2.  The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.

Authors:  Priya Samuel; David Raul Francisco Carter
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.